NCT04711915
Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
At risk: Primary completion moved 4 years later, enrollment reduced 67%.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 11 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Enrollment reduced: 30 → 10 participants Show 6 more changesShow less
- Primary completion pushed from Jul 1, 2026 to Jul 1, 2030
- Enrollment reopened
- Eligibility criteria expanded, about 6 words
- Study completion pushed from Dec 1, 2026 to Dec 1, 2030
- Interventions: 0.1 mg/kg Dimethyltryptamine (DMT) (Drug), 0.3 mg/kg Dimethyltryptamine (DMT) (Drug) to 0.1 mg/kg Dimethyltryptamine (DMT) (Drug), 0.3 mg/kg Dimethyltryptamine (DMT) (Drug)
- Site details revised
- Notable Primary completion date: Jul 1, 2025 to Jul 1, 2026
- Study completion date: Dec 1, 2025 to Dec 1, 2026
- Notable Primary completion date: Dec 1, 2024 to Jul 1, 2025
- Study completion date: Dec 1, 2024 to Dec 1, 2025
- Notable Primary and study completion dates pushed to Dec 1, 2024v9
- Notable Enrollment target: 6 to 30
- Primary completion date: Dec 1, 2021 to Dec 1, 2023
- Study completion date: Jun 1, 2022 to Jun 1, 2024
Show 5 earlier versionsHide 5 earlier versions
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Minor Start date changed from estimate of Mar 15, 2021 to Mar 17, 2021v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date: Mar 10, 2021 to Mar 15, 2021
- Minor Start date: Mar 1, 2021 to Mar 10, 2021v3
- Notable Eligibility criteria expanded, about 15 words
- Primary endpoints revised (6)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change in Blood Pressure
Timeframe: -60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration
Change in Heart Rate
Timeframe: -60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration
Change in Psychedelic Effects
Timeframe: -60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration
Change in Anxiety
Timeframe: -60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration
Drug Reinforcing Effects
Timeframe: +120 minutes after DMT administration
Overall Tolerability assessed by the VAS
Timeframe: +120 minutes after DMT administration
Arms and interventions
0.1 mg/kg DMTActive comparator
0.1 mg/kg DMT administered intravenously
0.3 mg/kg DMTActive comparator
0.3 mg/kg DMT administered intravenously
Drugs: 0.1 mg/kg Dimethyltryptamine (DMT), 0.3 mg/kg Dimethyltryptamine (DMT)
Sites
1 site in 1 country
- Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of MedicineWest Haven, Connecticut, United States